Adding Relacorilant To Nab-paclitaxel Prolongs Survival Compared with a Weekly Taxane in Patients with Platinum-Resistant Epithelial Ovarian Cancer By Ogkologos - June 23, 2025 782 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ROSELLA study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Stem cell research: meet the scientist growing ‘mini guts’ in her... April 8, 2022 What is De-escalation Treatment in Cancer Research? May 30, 2023 Long-Term Outcomes Suggest a Sustained Clinical Benefit to Metastasis-Directed Treatment Over... August 31, 2022 Mobile Care Center Brings Breast Cancer Treatment to Amish and Mennonite... December 18, 2019 Load more HOT NEWS Gut Microbes May Influence How Well Radiation Therapy Works against Cancer What to Know About Biomarker Testing for Lung Cancer: An Expert... Summer Sun Safety Tips Όροι χρήσης και προϋποθέσεις
